Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedJul 06, 2026
DataAggregated Company Financials
Companies21
  • 7D4.2%
  • 3M13.5%
  • 1Y-20.7%
  • YTD-11.0%

Over the last 7 days, the Pharma industry has risen 4.2%, driven by gains from Camurus of 3.3%. Meanwhile, Enzymatica actually underperformed within the industry, shrinking 6.8% in the last week. In the past year, the industry is down 21%. As for the next few years, earnings are expected to grow by 38% per annum.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 07 Jul 2026SEK 47.0bSEK 5.3b-SEK 1,275,205,144.0066.8x-36.9x8.9x
Thu, 04 Jun 2026SEK 42.4bSEK 5.3b-SEK 1,274,333,734.0065.4x-33.3x8x
Sat, 02 May 2026SEK 43.8bSEK 5.3b-SEK 1,208,469,671.0065.2x-36.3x8.3x
Mon, 30 Mar 2026SEK 39.5bSEK 5.3b-SEK 1,376,536,671.0052.2x-28.7x7.5x
Wed, 25 Feb 2026SEK 42.4bSEK 5.3b-SEK 1,338,444,873.0054.4x-31.7x8x
Fri, 23 Jan 2026SEK 53.5bSEK 5.3b-SEK 533,628,157.0069.8x-100.2x10.1x
Sun, 21 Dec 2025SEK 49.0bSEK 5.3b-SEK 531,735,157.0070.9x-92.2x9.2x
Tue, 18 Nov 2025SEK 50.0bSEK 5.3b-SEK 522,197,865.0068.3x-95.8x9.4x
Thu, 16 Oct 2025SEK 53.8bSEK 5.1b-SEK 405,183,865.0068.3x-132.9x10.6x
Sat, 13 Sep 2025SEK 58.5bSEK 5.1b-SEK 405,183,865.0079.1x-144.5x11.5x
Mon, 11 Aug 2025SEK 49.2bSEK 5.0b-SEK 45,588,364.0070.9x-1078.1x9.7x
Wed, 09 Jul 2025SEK 55.6bSEK 4.8b-SEK 525,205,364.0076.7x-105.8x11.6x
Fri, 06 Jun 2025SEK 52.8bSEK 4.8b-SEK 574,311,326.6870.4x-91.9x10.9x
Sun, 04 May 2025SEK 52.0bSEK 4.8b-SEK 940,419,211.3276.7x-55.3x10.9x
Tue, 01 Apr 2025SEK 48.5bSEK 4.7b-SEK 809,296,699.7669.5x-59.9x10.3x
Thu, 27 Feb 2025SEK 54.6bSEK 4.7b-SEK 761,845,969.1290.1x-71.7x11.6x
Sat, 25 Jan 2025SEK 49.8bSEK 4.4b-SEK 808,891,979.11122.9x-61.5x11.2x
Mon, 23 Dec 2024SEK 50.0bSEK 4.4b-SEK 615,836,627.11124.5x-81.1x11.2x
Wed, 20 Nov 2024SEK 48.6bSEK 4.4b-SEK 629,153,465.73120.3x-77.3x10.9x
Fri, 18 Oct 2024SEK 53.2bSEK 4.3b-SEK 676,942,257.87142.8x-78.7x12.4x
Sun, 15 Sep 2024SEK 68.1bSEK 5.9b-SEK 1,169,937,604.05180.3x-58.2x11.6x
Tue, 13 Aug 2024SEK 67.7bSEK 5.6b-SEK 993,383,168.2987.8x-68.2x12.1x
Thu, 11 Jul 2024SEK 69.6bSEK 6.4b-SEK 868,348,619.9083.3x-80.2x10.9x
Sat, 08 Jun 2024SEK 61.7bSEK 6.5b-SEK 871,189,906.3876.6x-70.8x9.5x
Mon, 06 May 2024SEK 49.6bSEK 6.3b-SEK 935,306,041.2466.4x-53x7.9x
Wed, 03 Apr 2024SEK 51.1bSEK 6.2b-SEK 1,038,139,273.2076.3x-49.3x8.2x
Fri, 01 Mar 2024SEK 46.5bSEK 6.2b-SEK 1,038,574,151.8478.5x-44.8x7.4x
Sun, 28 Jan 2024SEK 69.0bSEK 9.5b-SEK 1,181,839,895.0065.4x-58.4x7.3x
Tue, 26 Dec 2023SEK 68.0bSEK 9.4b-SEK 1,184,189,142.0063x-57.4x7.2x
Thu, 23 Nov 2023SEK 59.9bSEK 9.5b-SEK 1,172,189,523.0053x-51.1x6.3x
Sat, 21 Oct 2023SEK 50.7bSEK 9.2b-SEK 1,143,002,657.00104.7x-44.3x5.5x
Mon, 18 Sep 2023SEK 50.6bSEK 9.2b-SEK 1,177,933,411.00137.6x-43x5.5x
Wed, 16 Aug 2023SEK 52.1bSEK 8.9b-SEK 1,410,597,605.0087.7x-36.9x5.8x
Fri, 14 Jul 2023SEK 48.3bSEK 8.4b-SEK 1,693,125,975.0081.3x-28.5x5.8x
Price to Earnings Ratio

-28.5x


Total Market Cap: SEK 48.3bTotal Earnings: -SEK 1,693,125,975.00Total Revenue: SEK 8.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -74.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 9.3x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 14% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market3.03%
Healthcare4.58%
Pharma4.21%
Pharma4.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 579.504.5%
+SEK 1.5b		-14.1%PE50.6x
ALZCUR AlzeCure PharmaSEK 7.1283.0%
+SEK 534.8m		139.7%PB87.5x
SECARE SwedencareSEK 25.452.0%
+SEK 79.9m		-44.2%PE82.5x
FLERIE FlerieSEK 20.503.0%
+SEK 59.4m		-50.0%PS1128.4x
CINPHA Cinclus Pharma HoldingSEK 11.424.2%
+SEK 21.4m		-27.4%PS7.9x

Latest News

DICOT
SEK 0.19
Dicot Pharma
7D
-4.5%
1Y
-63.5%
FLERIE
SEK 20.50
Flerie
7D
3.0%
1Y
-50.0%
IRLAB A
SEK 1.31
IRLAB Therapeutics
7D
9.2%
1Y
-63.6%
ALZCUR
SEK 7.12
AlzeCure Pharma
7D
83.0%
1Y
139.7%
SECARE
SEK 25.45
Swedencare
7D
2.0%
1Y
-44.2%
Narrative Update • Jun 26

SECARE: I Expect Slower Acquisitions To Set Up A 2027 Upswing

Analysts have trimmed their Swedencare price target from SEK 55.00 to SEK 45.00, citing updated assumptions that now reflect a slightly higher discount rate, modestly lower revenue growth expectations, a higher projected profit margin, and a reduced future P/E multiple. What’s in the News for Swedencare Swedencare is actively seeking acquisitions, with management highlighting ongoing interest in adding new features and capabilities to the group.
CINPHA
SEK 11.42
Cinclus Pharma Holding
7D
4.2%
1Y
-27.4%
Narrative Update • Jun 25

CINPHA: Phase III GERD Readout And Trial Progress Will Support Future Upside

Analysts have maintained their SEK46.25 price target for Cinclus Pharma Holding, citing largely stable assumptions for revenue growth, profit margins and long term P/E expectations. What’s in the News for Cinclus Pharma Holding Cinclus Pharma Holding completed screening of patients in its pivotal Phase III HEEALING1 trial evaluating linaprazan glurate in erosive GERD, with approximately 500 patients enrolled across eight European countries.
ENZY
SEK 2.46
Enzymatica
7D
-2.0%
1Y
-14.0%
MOB
SEK 9.34
Moberg Pharma
7D
-1.5%
1Y
5.5%
Narrative Update • Jun 24

MOB: Expanded Licensing Network Will Drive Future Upside Potential

Analysts have kept their fair value estimate for Moberg Pharma steady at SEK 14.0 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E despite the updated price target data. What’s in the News for Moberg Pharma The first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, with commercial production and launch activities planned ahead of the high season, source: company key developments.
ONCOZ
SEK 7.06
OncoZenge
7D
-7.0%
1Y
10.7%
CAMX
SEK 579.50
Camurus
7D
4.5%
1Y
-14.1%
Narrative Update • Jun 17

CAMX: Expanded Lilly Cardiometabolic Collaboration Will Drive Future Upside Potential

Analysts have raised their price target on Camurus from SEK610 to SEK630 as they refresh their models for fair value, factoring in updated assumptions for the discount rate, revenue growth, profit margin and a higher future P/E multiple. What's in the News for Camurus Camurus announced that Eli Lilly has exercised its option to expand their collaboration and license agreement to include amylin receptor agonists, adding another class of cardiometabolic drug candidates using Camurus' FluidCrystal technology.
ORX
SEK 24.35
Orexo
7D
-0.2%
1Y
21.4%
Narrative Update • Jun 13

ORX: Overdose Reversal Pipeline Progress Will Support Future Upside

Orexo's SEK price target remains unchanged at SEK 29. Analysts have kept the fair value steady and point to relatively stable assumptions for the discount rate, revenue growth, profit margin and future P/E in their updated work.
GABA
SEK 0.034
Gabather
7D
-9.9%
1Y
-18.9%
NEWBRY
SEK 2.04
Newbury Pharmaceuticals
7D
14.3%
1Y
-31.1%
KLAR
SEK 0.81
Klaria Pharma Holding AB (publ.)
7D
3.5%
1Y
98.3%
CESSA
DKK 18.75
Cessatech
7D
-8.5%
1Y
63.3%
CLBIO
SEK 17.30
Corline Biomedical
7D
-4.7%
1Y
34.6%
Analysis Article • May 11

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...